CBG Isolate – Pure Cannabinoid
Cannabigerol | Non-Intoxicating Cannabinoid | Formulation & Blending Ingredient
Overview
CBG, or cannabigerol, is a non-intoxicating minor cannabinoid with a pharmacological profile distinct from both CBD and THC.
Often referred to as a foundational cannabinoid because its acidic precursor, CBGA, sits upstream of several major cannabinoids in the cannabis plant, CBG has attracted increasing research interest for its interactions with the endocannabinoid system, adrenergic receptors, serotonin signaling, and several other molecular targets.
Our CBG isolate is intended as a high-purity formulation ingredient for tinctures, capsules, edibles, topicals, custom cannabinoid blends, and other applications where precise cannabinoid ratios are required.
Rather than adding intoxication, CBG is commonly used to build functional, balanced, and non-psychoactive formulations.
Cannabinoid Profile
-
Cannabinoid: CBG
-
Full Name: Cannabigerol
-
Type: Pure Cannabinoid Isolate
-
Profile: Non-intoxicating
-
Primary Use: Formulation, blending, and cannabinoid ratio development
CBG interacts with cannabinoid receptors CB1 and CB2, but its pharmacology extends well beyond the conventional endocannabinoid system.
Research has identified activity at several targets, including:
-
CB1 and CB2 cannabinoid receptors
-
Alpha-2 adrenergic receptors
-
5-HT1A serotonin receptors
-
TRP ion channels
-
PPAR signaling pathways
This broad receptor activity gives CBG a distinctly different formulation role from simply adding more THC or CBD.
Clinical Research & Functional Profile
Human research on CBG remains early, but the evidence base is beginning to move beyond laboratory and animal studies.
Stress & Anxiety Research
A double-blind, placebo-controlled crossover trial published in 2024 evaluated 20mg of hemp-derived CBG in 34 healthy adults.
Compared with placebo, researchers observed significant reductions in self-reported anxiety and stress following CBG administration.
Importantly, the study found:
-
No evidence of subjective intoxication
-
No measurable motor impairment
-
No cognitive impairment
-
Improved performance on a verbal memory task
These results are preliminary and do not establish CBG as a treatment for anxiety disorders, but they provide useful human evidence supporting its reputation as a functional, non-intoxicating cannabinoid.
Non-Intoxicating Profile
CBG is generally characterized as non-intoxicating.
Controlled pharmacokinetic research has administered oral CBG isolate to adults without treating it as a conventional intoxicating cannabinoid, and recent human research has specifically evaluated doses ranging from 25mg through 200mg to better characterize its safety, pharmacodynamics, and absorption.
This makes CBG particularly useful in formulations intended for regular or functional use where a traditional THC-like high is undesirable.
Why Formulate With CBG?
CBG is unusually versatile because it can sit comfortably in both daytime and relaxation-oriented formulas.
It can be used to build:
-
Functional daytime blends
-
Relaxation-oriented cannabinoid formulas
-
CBD + CBG combinations
-
THCV + CBG formulations
-
CBG + CBC blends
-
Tinctures
-
Capsules
-
Edibles
-
Topicals
-
Custom minor-cannabinoid ratios
Its broad pharmacological activity makes it particularly useful as a supporting cannabinoid.
Rather than dominating the character of a formulation, CBG can provide another dimension to a cannabinoid blend while maintaining a non-intoxicating profile.
CBG is less about making a formula stronger and more about making it broader.
Pharmacology
CBG demonstrates a pharmacological profile that is considerably more complex than its classification as a minor cannabinoid might suggest.
Laboratory studies have found that CBG can act as a potent alpha-2 adrenergic receptor agonist and interact with 5-HT1A serotonin receptors. It also interacts with CB1 and CB2 cannabinoid receptors, including partial agonist activity reported at CB2.
These mechanisms have driven research into CBG across areas including neurological signaling, inflammation, gastrointestinal function, pain, and metabolic physiology.
However, much of this work remains preclinical, and these mechanisms should not be interpreted as evidence that CBG treats specific diseases.
Formulation Characteristics
Pure CBG isolate allows precise control over finished cannabinoid ratios.
It can be incorporated alongside:
For oral formulations, carrier system and dietary conditions can influence absorption. A human pharmacokinetic study found that both formulation type and dietary fat affected CBG exposure following oral administration.
This makes proper carrier selection, homogenization, and finished-product testing important when developing consistent CBG products.
Research Perspective
Current evidence suggests that CBG is:
-
Non-intoxicating under studied conditions
-
Pharmacologically distinct from CBD and THC
-
Active across several receptor systems
-
Increasingly studied in controlled human research
-
Potentially useful in functional cannabinoid formulations
At the same time, CBG research is still substantially less developed than research on CBD or THC.
Reviews of the evidence repeatedly emphasize that many proposed therapeutic applications remain based primarily on laboratory or animal studies and require larger controlled human trials.
Handling & Storage
Store tightly sealed in a cool, dark, dry environment away from excessive heat, moisture, and direct sunlight.
When using CBG isolate for finished-product manufacturing:
-
Accurately weigh cannabinoid input
-
Fully dissolve or disperse into the selected carrier
-
Homogenize thoroughly
-
Confirm finished potency through laboratory analysis
-
Use the accompanying certificate of analysis for batch-specific purity
Compliance & Safety
For formulation and adult-use cannabinoid applications where permitted by applicable law.
CBG is not approved by the FDA to diagnose, treat, cure, or prevent any disease. Human research remains limited, and individual responses may vary.
Consult appropriate technical, regulatory, and laboratory resources when developing finished cannabinoid products.
